CancerDrs

Lung Cancer clinical trials in Washington

55 actively recruiting lung cancer trials at 36 sites across Washington.

Data from ClinicalTrials.gov · last refreshed

Payments from drug makers to the doctors running these trials

For 3 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll. See the full lung cancer transparency page →

Phase 2, Phase 3 Recruiting Network

Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer

This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protoco…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT03851445
Sites in Washington:
  • Providence Regional Cancer System-Aberdeen — Aberdeen, Washington
  • MultiCare Auburn Medical Center — Auburn, Washington
  • FHCC Overlake — Bellevue, Washington
  • Overlake Medical Center — Bellevue, Washington
  • PeaceHealth Saint Joseph Medical Center — Bellingham, Washington
View on ClinicalTrials.gov →
Phase 3 Recruiting NIH

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04267848
Sites in Washington:
  • Providence Regional Cancer System-Aberdeen — Aberdeen, Washington
  • MultiCare Auburn Medical Center — Auburn, Washington
  • Overlake Medical Center — Bellevue, Washington
  • PeaceHealth Saint Joseph Medical Center — Bellingham, Washington
  • Highline Medical Center-Main Campus — Burien, Washington
View on ClinicalTrials.gov →
Phase 3 Recruiting NIH

Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04181060
Sites in Washington:
  • Providence Regional Cancer System-Aberdeen — Aberdeen, Washington
  • PeaceHealth Saint Joseph Medical Center — Bellingham, Washington
  • Highline Medical Center-Main Campus — Burien, Washington
  • Providence Regional Cancer System-Centralia — Centralia, Washington
  • Swedish Cancer Institute-Edmonds — Edmonds, Washington
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer

This phase III trial compares the effect of adding stereotactic body radiation therapy (SBRT) to the usual treatment (conventional image guided radiation therapy \[IGRT\] and chemotherapy followed by immunotherapy with durvalumab or target…

Sponsor: NRG Oncology
NCT ID: NCT05624996
Sites in Washington:
  • Virginia Mason Medical Center — Seattle, Washington
  • Legacy Cancer Institute Medical Oncology and Day Treatment — Vancouver, Washington
  • Legacy Salmon Creek Hospital — Vancouver, Washington
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting NIH

Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial

This phase II/III trial compares the effect of adding radiation therapy to the usual maintenance therapy with atezolizumab versus atezolizumab alone in patients who have already received atezolizumab plus chemotherapy for the treatment of …

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04402788
Sites in Washington:
  • PeaceHealth Saint Joseph Medical Center — Bellingham, Washington
  • Saint Joseph Medical Center Hematology and Oncology - Silverdale — Silverdale, Washington
  • Legacy Cancer Institute Medical Oncology and Day Treatment — Vancouver, Washington
  • Legacy Salmon Creek Hospital — Vancouver, Washington
View on ClinicalTrials.gov →
Phase 3 Recruiting NIH

Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial

This phase III trial compares the effect of adding chemotherapy to immunotherapy (pembrolizumab) versus immunotherapy alone in treating patients with stage IIIB-IV lung cancer. Immunotherapy with monoclonal antibodies, such as pembrolizuma…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06096844
Sites in Washington:
  • Swedish Cancer Institute-Edmonds — Edmonds, Washington
  • Swedish Cancer Institute-Issaquah — Issaquah, Washington
  • Swedish Medical Center-First Hill — Seattle, Washington
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain

This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radia…

Sponsor: NRG Oncology
NCT ID: NCT06500455
Sites in Washington:
  • Valley Medical Center — Renton, Washington
  • Legacy Cancer Institute Medical Oncology and Day Treatment — Vancouver, Washington
  • Legacy Salmon Creek Hospital — Vancouver, Washington
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma

This phase III trial compares the effect of open thoracic surgery (thoracotomy) to thoracoscopic surgery (video-assisted thoracoscopic surgery or VATS) in treating patients with osteosarcoma that has spread to the lung (pulmonary metastase…

Sponsor: Children's Oncology Group
NCT ID: NCT05235165
Sites in Washington:
  • Overlake Medical Center — Bellevue, Washington
  • Valley Medical Center — Renton, Washington
  • Seattle Children's Hospital — Seattle, Washington
  • Providence Sacred Heart Medical Center and Children's Hospital — Spokane, Washington
  • Mary Bridge Children's Hospital and Health Center — Tacoma, Washington
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

The purpose of this study is to understand if PF-08046054 alone works well compared to standard-of-care docetaxel alone in participants with non-small cell lung cancer (NSCLC) with PD-L1 expression greater than or equal to 1% and had cance…

Sponsor: Pfizer
NCT ID: NCT07144280
Sites in Washington:
  • American Oncology Network Vista Oncology Division-West office — Olympia, Washington
  • American Oncology Network Vista Oncology Division-East office — Olympia, Washington
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor

Multicenter, randomized (2:1), open-label phase 3 study in HLA-A2 positive patients with squamous and non-squamous metastatic NSCLC with ICI secondary resistance. Patients will be randomized into 2 arms (randomization 2:1): experimental Ar…

Sponsor: OSE Immunotherapeutics
NCT ID: NCT06472245
Sites in Washington:
  • Northwest Medical Specialties - Bonney Lake — Bonney Lake, Washington
  • Northwest Medical Specialties - Federal Way — Federal Way, Washington
  • Northwest Medical Specialties - Gig Harbor — Gig Harbor, Washington
  • Northwest Medical Specialties - Puyallup Medical Oncology — Puyallup, Washington
  • Northwest Medical Specialties - Tacoma — Tacoma, Washington
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)

The goal of this study is to evaluate intismeran autogene plus pembrolizumab versus placebo plus pembrolizumab for the adjuvant treatment of margin negative, completely resected Stage II, IIIA, IIIB (with nodal involvement \[N2\]) non-smal…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06077760
Sites in Washington:
  • Swedish Medical Center-Swedish Cancer Institute ( Site 0088) — Seattle, Washington
  • Fred Hutchinson Cancer Center ( Site 0002) — Seattle, Washington
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

The purpose of this study is to evaluate efficacy and safety of Dato-DXd in combination with rilvegostomig or rilvegostomig monotherapy compared with pembrolizumab monotherapy as a first line therapy in participants with locally advanced o…

Sponsor: AstraZeneca
NCT ID: NCT06357533
Sites in Washington:
  • Research Site — Tacoma, Washington
  • Research Site — Vancouver, Washington
  • Research Site — Wenatchee, Washington
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

The goal of this study is to learn if people who receive intismeran autogene and pembrolizumab after surgery are cancer-free longer than people who receive placebo and pembrolizumab. Researchers want to know if giving intismeran autogene a…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06623422
Sites in Washington:
  • Swedish Cancer Institute ( Site 0143) — Seattle, Washington
  • St. Joseph Medical Center Hematology and Oncology - Silverdale ( Site 0192) — Silverdale, Washington
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell lung cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. The purpose of this study…

Sponsor: AbbVie
NCT ID: NCT04928846
Sites in Washington:
  • Valley Medical Center /ID# 253950 — Renton, Washington
  • Medical Oncology Associates /ID# 247003 — Spokane, Washington
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting Industry

A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

The purpose of this study is to compare the clinical benefit of the combination of Navlimetostat (BMS-986504) (a selective MTA-cooperative inhibitor of PRMT5) plus pembrolizumab and chemotherapy versus placebo plus pembrolizumab and chemot…

Sponsor: Bristol-Myers Squibb
NCT ID: NCT07063745
Sites in Washington:
  • Fred Hutchinson Cancer Center — Seattle, Washington
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)

The purpose of this study is to evaluate the efficacy of Pumitamig versus Pembrolizumab in participants with previously untreated advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%.

Sponsor: Bristol-Myers Squibb
NCT ID: NCT07361510
Sites in Washington:
  • Local Institution - 0384 — Spokane, Washington
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC

This study, known as LUNAR-2, aims to investigate the effectiveness and safety of using TTFields, delivered by the NovoTTF-200T device, concomitantly administered with pembrolizumab and platinum-based chemotherapy for patients with advance…

Sponsor: NovoCure GmbH
NCT ID: NCT06216301
Sites in Washington:
  • MultiCare Regional Cancer Center — Auburn, Washington
  • MultiCare Regional Cancer Center — Gig Harbor, Washington
  • MultiCare Regional Cancer Center — Puyallup, Washington
  • MultiCare Deaconess Cancer and Blood Specialty Center - Downtown — Spokane, Washington
  • MultiCare Institute for Research & Innovation — Tacoma, Washington
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

This study will assess the effect of Dato-DXd in combination with osimertinib or Dato-DXd monotherapy versus platinum-based doublet chemotherapy in terms of progression-free survival (PFS).

Sponsor: AstraZeneca
NCT ID: NCT06417814
Sites in Washington:
  • Research Site — Seattle, Washington
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC

Multicenter, randomized, controlled, open-label, Phase 3 study designed to demonstrate that neladalkib (NVL-655) is superior to alectinib in prolonging progression-free survival (PFS) in patients with treatment-naïve, Anaplastic Lymphoma K…

Sponsor: Nuvalent Inc.
NCT ID: NCT06765109
Sites in Washington:
  • University of Washington - Fred Hutchinson Cancer Center — Seattle, Washington
  • Compass Oncology — Vancouver, Washington
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In

This is a randomized, two-cohort, open-label, phase 3, clinical trial to compare the efficacy and safety of N-803 plus tislelizumab and docetaxel (cohort A) or prior failed Health Authority-approved antiprogrammed death-1 (PD-1) or anti-pr…

Sponsor: ImmunityBio, Inc.
NCT ID: NCT06745908
Sites in Washington:
  • Medical Oncology Associates - Summit Cancer Centers — Spokane, Washington
View on ClinicalTrials.gov →
Phase 2 Recruiting Network

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

This phase II Lung-MAP treatment trial test the combination of targeted drugs (capmatinib, osimertinib, and/or ramucirumab) in treating patients with non-small cell lung cancer that may have spread from where it first started to nearby tis…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT05642572
Sites in Washington:
  • FHCC Overlake — Bellevue, Washington
  • FHCC at EvergreenHealth — Kirkland, Washington
  • Valley Medical Center — Renton, Washington
  • Fred Hutchinson Cancer Center — Seattle, Washington
  • Swedish Medical Center-First Hill — Seattle, Washington
View on ClinicalTrials.gov →
Phase 2 Recruiting Network

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

This phase II Expanded Lung-MAP treatment trial tests tepotinib with or without ramucirumab for the treatment of patients with advanced non-small cell lung cancer that has spread from where it first started (primary site) to other places i…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT06031688
Sites in Washington:
  • Swedish Cancer Institute-Edmonds — Edmonds, Washington
  • Swedish Cancer Institute-Issaquah — Issaquah, Washington
  • Swedish Medical Center-First Hill — Seattle, Washington
View on ClinicalTrials.gov →
Phase 2 Recruiting Network

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)

This phase II Expanded Lung-MAP treatment trial tests how well amivantamab-subcutaneous (SC) works in treating patients patients with MET amplification non-small cell lung cancer. Amivantamab-SC is a drug that reduces extra copies of the M…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT06116682
Sites in Washington:
  • Swedish Cancer Institute-Edmonds — Edmonds, Washington
  • Swedish Cancer Institute-Issaquah — Issaquah, Washington
  • Swedish Medical Center-First Hill — Seattle, Washington
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell lung cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. The purpose of this study…

Sponsor: AbbVie
NCT ID: NCT06568939
Sites in Washington:
  • Medical Oncology Associates - Spokane /ID# 277172 — Spokane, Washington
  • Northwest Medical Specialties Tacoma /ID# 270534 — Tacoma, Washington
View on ClinicalTrials.gov →

Showing 25 of 55 trials with sites in Washington. See all lung cancer trials →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-08-17